[Featured Stock] Kwang Dong Pharmaceutical Hits Upper Limit on 'Presbyopia Treatment FDA Approval'
Kwang Dong Pharmaceutical's share price has been rising for two consecutive days on news that a treatment for which it holds exclusive distribution rights in Korea has received approval from the U.S. Food and Drug Administration (FDA).
As of 9:10 a.m. on the 20th, Kwang Dong Pharmaceutical was trading at 10,400 won, up 30.00% (2,400 won) from the previous trading day.
The previous day as well, Kwang Dong Pharmaceutical surged 29.87% from the previous session to close at the upper price limit of 8,000 won.
Earlier, Kwang Dong Pharmaceutical announced that Uvegi, a presbyopia treatment for which it holds exclusive distribution rights in Korea, had received FDA approval.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Uvegi is a new drug developed by global biotech company Tenpoint Therapeutics, and in January 2024 Kwang Dong Pharmaceutical signed an exclusive license agreement with Hong Kong pharmaceutical company Zaoker, which holds the rights for the Asian region to this drug.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.